Syed Gilani, MD
Interventional Cardiology · Clearwater, FLNPI 1265483143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Boston Scientific at 25.1% of the total. Reporting peaked in 2019 at $726 and has fallen 77.9% since, to $160 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 85 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$580
- Abiomed$341
- Cardiovascular Systems Inc.$224
- AstraZeneca$187
- Novartis$159
- Pfizer$155
- plus $666 from 17 others
Across 19 payments — averaging $28,819 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$310K
- Novartis$213K
- Bayer$25K
What the payments were for
- Food & beverage$2,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $580 |
| Abiomed | 6 | $341 |
| Cardiovascular Systems Inc. | 10 | $224 |
| AstraZeneca | 11 | $187 |
| Novartis | 9 | $159 |
| Pfizer | 6 | $155 |
| Inspire Medical Systems, Inc. | 1 | $122 |
| Amgen | 5 | $90 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $72 |
| Medtronic | 1 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $54 |
| Biosense Webster, Inc. | 2 | $36 |
| AbbVie | 2 | $35 |
| Boehringer Ingelheim | 2 | $29 |
| Vifor Pharma, Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Terumo Medical Corporation | 1 | $17 |
| Bracco Diagnostics Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,311 in reported general payments places this provider in the 15th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 337 | $385,010 |
| EntrestoSacubitril/Valsartan | 89 | $106,264 |
| XareltoRivaroxaban | 49 | $67,197 |
| Repatha SureclickEvolocumab | 59 | $55,987 |
| BrilintaTicagrelor | 48 | $32,700 |
| FarxigaDapagliflozin Propanediol | 15 | $16,427 |
| Dofetilide | 30 | $5,542 |
| Metoprolol Succinate | 336 | $4,061 |
| Atorvastatin Calcium | 416 | $3,661 |
| Flecainide Acetate | 58 | $2,516 |
| Losartan Potassium | 210 | $2,315 |
| Metoprolol Tartrate | 307 | $1,975 |
| Carvedilol | 237 | $1,938 |
| ClopidogrelClopidogrel Bisulfate | 119 | $1,465 |
| Nifedipine ErNifedipine | 62 | $1,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $155 | $385,010337 claims |
| NovartisEntresto | $159 | $106,26489 claims |
| Johnson & JohnsonXarelto | $24 | $67,19749 claims |
| AstraZenecaBrilinta, Farxiga | $187 | $49,12663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Clearwater
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.